Literature DB >> 14985123

Protease inhibitors prevent the protein kinase A-dependent loss of Rap1 GTPase from the particulate fraction of COS1 cells.

Catherine J Rundell1, Claire E Repellin, Stephen J Yarwood.   

Abstract

Immunoblotting with a monoclonal Rap1 antibody, we found that elevation of cyclic AMP, with forskolin and IBMX or CPT-cAMP, led to a rapid reduction in the levels of Rap1 protein associated with particulate, nuclear/perinuclear fractions from PC12 and COS1 cells. In contrast, cytoplasmic levels of Rap1 remained constant following cyclic AMP stimulation. To gain independent confirmation that cyclic AMP promoted loss of Rap1 in nuclear/perinuclear fractions we used a polyclonal Rap1 antibody, which gave similar results to the monoclonal antibody. This demonstrated that the loss in Rap1 immunoreactivity was not due to phosphorylation-dependent changes that alter immunorecognition. The reduction in Rap1 levels was blocked by PKA inhibitors and by a Rap1 serine to alanine PKA-phosphorylation site mutant (S180A). Peptide inhibitors of the proteasome, cathespin, and calpain II also inhibited the decrease in Rap1 levels, indicating that proteolytic degradation may contribute to maintaining Rap1 levels in the nuclear/perinuclear fraction of cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14985123     DOI: 10.1016/j.bbrc.2004.01.161

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Protein kinase A-dependent phosphorylation of Rap1 regulates its membrane localization and cell migration.

Authors:  Maho Takahashi; Tara J Dillon; Chang Liu; Yumi Kariya; Zhiping Wang; Philip J S Stork
Journal:  J Biol Chem       Date:  2013-08-14       Impact factor: 5.157

2.  Rap1-mediated activation of extracellular signal-regulated kinases by cyclic AMP is dependent on the mode of Rap1 activation.

Authors:  Zhiping Wang; Tara J Dillon; Viji Pokala; Snigdha Mishra; Kirstin Labudda; Brian Hunter; Philip J S Stork
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

3.  Targeting protein prenylation for cancer therapy.

Authors:  Norbert Berndt; Andrew D Hamilton; Saïd M Sebti
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.